Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan
18 juin 2019 09h05 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight, and follow...
Progenics to Mail Letter to Shareholders
13 juin 2019 17h00 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial...
Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer
13 juin 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting
06 juin 2019 07h45 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Announces Updated Survival Data for AZEDRA® (iobenguane I 131) in Advanced Pheochromocytoma and Paraganglioma
03 juin 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
- Long-Term Follow Up Data from Pivotal Study Presented at ASCO -- Patients Treated with AZEDRA Show Overall Survival of 73.1% at Two Years and 44.2% at Four Years - NEW YORK, June 03, 2019 (GLOBE...
Progenics Pharmaceuticals Mails Letter to Shareholders
03 juin 2019 08h00 HE
|
Progenics Pharmaceuticals Inc.
Asks Shareholders to Vote “FOR” All the Company’s Qualified Directors on the WHITE Proxy Card NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics”...
Progenics Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
30 mai 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
23 mai 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration for Prostate Cancer Imaging Agent 1404
14 mai 2019 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK & DRESDEN, Germany, May 14, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial...
Progenics Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update
09 mai 2019 07h45 HE
|
Progenics Pharmaceuticals Inc.
AZEDRA® (iobenguane I 131) U.S. Commercial Launch Advancing with 22 Treatment Requests from Patients Received and 12 Centers Throughout the U.S. are Ready to Treat PatientsPhase 2 Trial of 1095...